Dealert Deals Biometrics and Data Services business unit of Firma Clinical Research

Everest Clinical Research, Arlington Capital Partners Biometrics and Data Services business unit of Firma Clinical Research

Buyout United States of America Biotechnology & Medical Research (NEC) Corporate / Strategic Seller
Deal summary

Information on the target

Everest Clinical Research (“Everest”) is a data-first, full-service clinical research organization that specializes in providing comprehensive clinical development services. The company has recently announced its acquisition of the Biometrics and Data Services business unit from Firma Clinical Research (“Firma DS”). This strategic move is aimed at enhancing Everest’s global biometrics expertise and clinical data science capabilities, thereby solidifying its position in the competitive landscape of clinical research.

Firma DS has established itself as a key player in the biotechnology and pharmaceutical sectors, offering biometrics and clinical data services that support a wide range of clients, including biotechnology, pharmaceutical, medical device, and diagnostic companies. With a proven track record of supporting over 1,000 clinical studies and more than 60 New Drug Application (NDA) submissions, Firma DS has demonstrated its capability in complex therapeutic areas such as oncology, neurology, rare diseases, hepatology, and nephrology.

Industry overview in the target’s specific country

The Biotechnology & Medical Research (NEC) industry in Canada has been experiencing significant growth, driven by advancements in technology and an increasing focus on innovative healthcare solutions. Canada is recognized for its robust research infrastructure, which includes world-class universities and research institutions that foster collaboration between academia and industry. This environment has led to a thriving ecosystem for biotechnology firms, particularly in the fields of drug development and clinical research.

In recent years, the Canadian government has implemented various initiatives to support the biotechnology sector, including funding programs and tax incentives aimed at encouraging research and development. These efforts have attracted both domestic and international investments, positioning Canada as a favorable location for biotechnology companies seeking to conduct clinical trials and develop new therapies.

The demand for clinical research services in Canada is further bolstered by the increasing complexity of clinical trials and the need for specialized expertise in data management and biometrics. As the industry evolves, companies are seeking partners that can provide integrated solutions to navigate the regulatory landscape and ensure compliance with stringent guidelines. This trend highlights the importance of organizations like Everest, which are equipped to deliver comprehensive support throughout the clinical development lifecycle.

Moreover, the COVID-19 pandemic has accelerated the adoption of digital health technologies and remote monitoring solutions, reshaping the clinical research landscape. As a result,…

This is a public preview. The full deal page — disclosed financials, full description, advisers, comparable set — is available with a free account.
Create free account
View primary source ↗